Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Brand Names
- Acthib, Pentacel
- Generic Name
- Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
- DrugBank Accession Number
- DB10076
- Background
Haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen is a vaccine for intramuscular injection used in the prevention of invasive disease caused by Haemophilus influenzae type b. H. influenzae is a Gram-negative coccobacillus that can cause infections including sepsis and meningitis. The vaccine contains the Haemophilus influenzae type b capsular polysaccharide (polyribosyl-ribitol-phosphate, PRP), a high-molecular-weight polymer prepared from the H. influenzae type b strain 1482 grown in a semi-synthetic medium, covalently bound to tetanus toxoid 1. The toxoid antigen is purified and toxin-inactivated.
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Vaccines
Inactivated / Toxoid / Conjugate - Synonyms
- Haemophilus influenzae type B strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Prevention of Invasive infection caused by haemophilus influenzae type b •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image ActHIB Injection, powder, lyophilized, for solution; Kit 10 ug/0.5mL Intramuscular Sanofi Pasteur Inc. 1993-03-30 Not applicable US 
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Act-hib Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (10 mcg) Kit; Powder, for solution Intramuscular Sanofi Pasteur Limited 1992-12-31 Not applicable Canada 
Infanrix-hexa Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (10 mcg / 0.5 mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg / 0.5 mL) + Bordetella pertussis pertactin antigen (8 mcg / 0.5 mL) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (25 mcg / 0.5 mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 mcg / 0.5 mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (10 lf / 0.5 mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (25 lf / 0.5 mL) + Hepatitis B Vaccine (Recombinant) (10 mcg / 0.5 mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 unit / 0.5 mL) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 unit / 0.5 mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 unit / 0.5 mL) Suspension Intramuscular Glaxosmithkline Inc 2008-12-04 Not applicable Canada Menhibrix Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (2.5 ug/0.5mL) + Meningococcal polysaccharide vaccine group C (5 ug/0.5mL) + Meningococcal polysaccharide vaccine group Y (5 ug/0.5mL) Injection, powder, lyophilized, for solution Intramuscular GlaxoSmithKline Biologicals SA 2013-09-03 2013-11-27 US Menhibrix Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (2.5 ug/0.5mL) + Meningococcal polysaccharide vaccine group C (5 ug/0.5mL) + Meningococcal polysaccharide vaccine group Y (5 ug/0.5mL) Kit Intramuscular GlaxoSmithKline Biologicals SA 2013-09-03 2017-09-17 US Pediacel Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (10 mcg / 0.5 mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (20 mcg / 0.5 mL) + Bordetella pertussis fimbriae 2/3 antigen (5 mcg / 0.5 mL) + Bordetella pertussis pertactin antigen (3 mcg / 0.5 mL) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (20 mcg / 0.5 mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 lf / 0.5 mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (15 lf / 0.5 mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 unit / 0.5 mL) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 unit / 0.5 mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 unit / 0.5 mL) Suspension Intramuscular Sanofi Pasteur Limited 2007-10-04 Not applicable Canada
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- FLV5I5W26R
- CAS number
- Not Available
References
- General References
- Dailymed Label: ACTHIB- haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen [Link]
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Prevention Acute Lymphoblastic Leukemia (ALL) 1 4 Completed Prevention BCG Infection / Immune Responses / Vaccine Reaction 1 4 Completed Prevention Diphtheria / Haemophilus Influenzae Serotype b (Hib) / Meningitis / Meningococcal Infections / Pertussis / Tetanus 1 4 Completed Treatment Pain 1 3 Completed Prevention Acellular Pertussis / Diphtheria / Haemophilus Influenzae Serotype b (Hib) / Poliomyelitis / Tetanus / Viral Hepatitis B 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Kit; powder, for solution Intramuscular Injection, powder, for solution Intramuscular 10 µg/0.5mL Injection, powder, lyophilized, for solution; kit Intramuscular 10 ug/0.5mL Suspension Intramuscular Injection, powder, lyophilized, for solution Intramuscular Kit Intramuscular Injection; injection, suspension; kit Intramuscular Injection, powder, for suspension Intramuscular Liquid Intramuscular Injection, suspension Intramuscular - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at November 30, 2015 21:23 / Updated at November 28, 2021 16:22